Literature DB >> 9885234

Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity.

J W Semple1, E R Speck, D Cosgrave, A H Lazarus, V S Blanchette, J Freedman.   

Abstract

In a murine model of platelet alloimmunization, we examined the definitive role that mononuclear cells (MC) have in modulating platelet immunity by using platelets from severe combined immunodeficient (SCID) mice. CB.17 (H-2(d)) SCID or BALB/c (H-2(d)) mouse platelets were transfused weekly into fully allogeneic CBA (H-2(k)) mice and antidonor antibodies measured by flow cytometry. MC levels in BALB/c platelets were 1.1 +/- 0.6/microL and SCID mouse platelets could be prepared to have significantly lower (<0. 05/microL) MC numbers. Transfusions with 10(8) BALB/c platelets (containing approximately 100 MC/transfusion) stimulated IgG antidonor antibodies in 100% of the recipients by the fifth transfusion, whereas 10(8) SCID mouse platelets (containing approximately 5 MC/transfusion) stimulated higher-titered IgG alloantibodies by the second transfusion. When titrations of BALB/c peripheral blood MC were added to the SCID mouse platelets, levels approaching 1 MC/microL reduced SCID platelet immunity to levels similar to BALB/c platelets. Characterization of the alloantibodies showed that the low levels of MC significantly influenced the isotype of the antidonor IgG; the presence of 1 MC/microL was associated with induction of noncomplement fixing IgG1 antidonor antibodies, whereas platelet transfusions, devoid of MC (<0. 05/microL), were responsible for complement-fixing IgG2a production. When magnetically sorted defined subpopulations of MC were added to the SCID platelets, major histocompatability complex (MHC) class II positive populations, particularly B cells, were found to be primarily responsible for the reduced SCID mouse platelet immunity. The presence of low numbers of MC within the platelets was also associated with an age-dependent reduction in platelet immunogenicity; this relationship however, was not observed with SCID mouse platelets devoid of MC. The results suggest that a residual number of MHC class II positive B cells within allogeneic platelets are required for maximally reducing alloimmunization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9885234

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  CD8+ T cells mediate antibody-independent platelet clearance in mice.

Authors:  Connie M Arthur; Seema R Patel; H Cliff Sullivan; Annie M Winkler; Chris A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

2.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

3.  MHC II on transfused murine blood is not required for alloimmunization against MHC I.

Authors:  C R Gilson; C M Cadwell; N H Smith; J E Hendrickson; J C Zimring
Journal:  Vox Sang       Date:  2010-11       Impact factor: 2.144

Review 4.  Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

Authors:  Seema R Patel; James C Zimring
Journal:  Transfus Med Rev       Date:  2013-10-03

5.  Alloimmunogenicity of an isolated MHC allele is affected by the context of MHC mismatch in a murine model.

Authors:  Krystalyn E Hudson; Andrea S L Wong; Amanda L Richards; Linda M Kapp; James C Zimring
Journal:  Transfusion       Date:  2019-01-25       Impact factor: 3.157

6.  Lipopolysaccharide is a direct agonist for platelet RNA splicing.

Authors:  Pavel N Shashkin; G Thomas Brown; Arundhati Ghosh; Gopal K Marathe; Thomas M McIntyre
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice.

Authors:  Seema R Patel; Chantel M Cadwell; Arielle Medford; James C Zimring
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.